BiotechTubeBiotechTube
Home/Pipeline/Interferon β-1a

Interferon β-1a

Multiple Sclerosis

CommercialActive collaboration with GlyTech

Key Facts

Indication
Multiple Sclerosis
Phase
Commercial
Status
Active collaboration with GlyTech
Company
Bachem

About Bachem

Founded in 1971 and headquartered in Switzerland, Bachem has evolved from a specialized peptide laboratory into a global leader in TIDES manufacturing with over 1,200 employees worldwide. The company operates through an integrated platform covering clinical development, GMP manufacturing, and custom synthesis services for both peptides and oligonucleotides. With facilities in Switzerland, the US, and subsidiaries globally, Bachem serves as a trusted manufacturing partner to pharmaceutical and biotech companies developing innovative therapeutic products.

View full company profile

Therapeutic Areas

Multiple therapeutic areas via CDMO servicesMultiple SclerosisVarious pharmaceutical applications

Other Multiple Sclerosis Drugs

DrugCompanyPhase
Zeposia (ozanimod)Bristol Myers SquibbCommercial
Copaxone (glatiramer acetate)Teva Pharmaceutical IndustriesCommercial
Multiple Sclerosis PortfolioBiogenCommercial
Kesimpta (ofatumumab)GenmabApproved
Glatiramer Acetate (Generic Copaxone)Dr. Reddy's LaboratoriesApproved
Glatiramer AcetateCiplaCommercial
KYV-101Kyverna TherapeuticsPhase 1/2
Azer-cel (PBCAR0191)Precision BioSciencesPhase 1/2
CYMS101FibroBiologicsPre-clinical / Limited Clinical